The effects of nonspecific HIF 1 α inhibitors on development of castrate resistance and metastases in prostate cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Expression of hypoxia‐inducible factor (HIF)1 α increases the risk of castrate‐resistant prostate cancer (CRPC) and metastases in patients on androgen deprivation therapy (ADT) for prostate cancer (PC). We aimed to investigate the effects of nonspecific HIF 1 α inhibitors (Digoxin, metformin, and angiotensin‐2 receptor blockers) on development of CRPC and metastases while on ADT. A retrospective review of prospectively collected medical records was conducted of all men who had continuous ADT as first‐line therapy for CRPC at the Austin Hospital from 1983 to 2011. Association between HIF 1 α inhibitor medications and time to develop CRPC was investigated using actuarial statistics. Ninety‐eight patients meeting the criteria were identified. Eighteen patients (21.4%) were treated with the nonspecific HIF 1 α inhibitors. Both groups had similar characteristics, apart from patients on HIF 1 α inhibitors being older (70 years vs. 63.9 years). The median CRPC‐free survival was longer in men using HIF 1 α inhibitors compared to those not on inhibitors (6.7 years vs. 2.7 years, P = 0.01) and there was a 71% reduction in the risk of developing CRPC (HR 0.29 [95% CI 0.10–0.78] P = 0.02) after adjustment for Gleason score, age, and prostate‐specific antigen (PSA). The median metastasis‐free survival in men on HIF 1 α inhibitors was also significantly longer compared to those on no inhibitors (5.1 years vs. 2.6 years, P = 0.01) with an 81% reduction in the risk of developing metastases (HR 0.19 [CI 0.05–0.76] P = 0.02) after adjustment for Gleason score, age, and PSA. Nonspecific HIF 1 α inhibitors appear to increase the progression‐free survival and reduce the risk of developing CRPC and metastases in patients on continuous ADT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“However, the disease progresses and castrate-resistant prostate cancer (CRPC) develops in a significant proportion of men while on ADT [1].”
BackgroundMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 1×
“Expression of androgen receptors has been linked with development of castrate resistance [8], and shown to be upregulated by HIF1a [9].”
BackgroundKirby, M., Hirst, C., & Crawford, E. D. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02799.x · Cited by 861 · cited 1×
“In some series greater than 84% of CRPC patients have metastases at diagnosis, while a further 33% of patients who do not have metastases at the diagnosis of CRPC may be expected to develop metastases within 2 years [3].”
BackgroundDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624
Cited by
Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes
Tirpe, A. A., Gulei, D., Ciortea, S. M., Crivii, C., & Berindan-Neagoe, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246140 · Cited by 438
Hypoxia-Inducible Factors and Cancer
Jun, J. C., Rathore, A., Younas, H., Gilkes, D., & Polotsky, V. Y. (2017) · Current Sleep Medicine Reports · doi:10.1007/s40675-017-0062-7 · Cited by 248
Brownfoot, F. C., Hastie, R., Hannan, N. J., Cannon, P., Tuohey, L., Parry, L. J., Senadheera, S., Illanes, S. E., Kaitu’u-Lino, T. J., & Tong, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.12.019 · Cited by 222
Alghandour, R., Ebrahim, M. A., Elshal, A. M., Ghobrial, F., Elzaafarany, M., & ELbaiomy, M. A. (2021) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2021.05.020 · Cited by 49
Metadata
- Authors
- Ranasinghe, W. K. B., Sengupta, S., Williams, S., Chang, M., Shulkes, A., Bolton, D. M., Baldwin, G., & Patel, O.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2014-01-27
- Volume
- 3
- Issue
- 2
- Pages
- 245-251
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2153784080
- Cited by
- 36
- References
- 4
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of nonspecific HIF 1 α inhibitors on development of castrate resistance and metastases in prostate cancer. https://app.cochat.ai/papers/10.1002/cam4.189
- The paper
- Ranasinghe, W. K. B., Sengupta, S., Williams, S., Chang, M., Shulkes, A., Bolton, D. M., Baldwin, G., & Patel, O. (2014). The effects of nonspecific HIF 1 α inhibitors on development of castrate resistance and metastases in prostate cancer. Cancer Medicine. https://doi.org/10.1002/cam4.189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.